Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced its participation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 2:00 p.m. Eastern Time in Toronto, Ontario. Key executives, including President and CEO David R. Parkinson, COO Peter Virsik, and CFO David S. Wood, will engage in one-on-one meetings with investors.
The conference connects U.S. and Canadian investors with updates on the Canadian healthcare sector and features both presentations and private meetings with prominent companies. A live webcast of ESSA's presentation will be available on the company’s website, with an archived version accessible for 90 days thereafter.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
